Pet Vaccines Market Forecasts to 2034 - Global Analysis By Vaccine Type, Animal Type, Disease Indication, Route of Administration, Distribution Channel, Vaccine Valency, End User, and By Geography

According to Stratistics MRC, the Global Pet Vaccines Market is accounted for $5.9 billion in 2026 and is expected to reach $13.2 billion by 2034 growing at a CAGR of 10.6% during the forecast period. The market covers preventive and selected therapeutic immunization for dogs, cats and other companion animals, including core and non-core vaccines, combination formulations, and disease-specific products. It is used to reduce infectious-disease incidence and support population-level animal health. Growth reflects routine preventive-care uptake and pathogen surveillance and continued vaccine innovation. Market expansion is likely to vary with purchasing power, product performance, regulatory requirements and channel reach.

Market Dynamics:

Driver:

Routine preventive care and risk-based vaccination protocols

Routine preventive-care visits remain the primary channel for pet vaccination, while risk-based protocols increasingly shape product selection by age, lifestyle, travel and exposure. Veterinarians recommend core vaccines for population health and non-core vaccines for animals at higher risk, supporting repeat demand and predictable scheduling. Owner awareness, reminder systems and clinic access improve compliance, and continued innovation in combination and next-generation vaccines sustains interest. As preventive care becomes more personalized, demand is likely to remain steady across dogs, cats and other companion animals.

Restraint:

Variable vaccine access and owner concerns about cost or adverse events

Vaccine access varies by geography, clinic capacity and distribution reach, and owners may delay or decline vaccination because of cost, convenience or concern about adverse events. Differences in professional recommendations and uneven owner awareness can also reduce confidence, especially where product information is limited. In remote or price-sensitive households, access to trained providers and affordable products remains constrained. Suppliers and clinics need clear safety communication, transparent pricing and reliable supply to address hesitancy and support consistent vaccination uptake.

Opportunity:

Combination products and improved preventive-care delivery

Combination vaccines and improved delivery models can reduce visit burden, simplify protocols and improve compliance. Practitioner partnerships, reminder systems, online education and clinic-led follow-up can help owners understand timing and risk-based recommendations. Tailored formats and clearer labeling can differentiate products in competitive markets. There is also scope to extend preventive care to underserved life stages and multi-pet households through coordinated veterinary, retail and digital channels. Providers that combine credible evidence with convenient access can strengthen retention and broaden adoption beyond major urban centers.

Threat:

Pathogen shifts, safety scrutiny and manufacturing disruption

Pathogen evolution, emerging disease patterns and changes in circulating strains can reduce the fit of existing vaccines and require ongoing surveillance. Safety scrutiny and adverse-event reporting may increase regulatory and reputational pressure, while manufacturing disruption, ingredient shortages or distribution constraints can affect supply. Competition from lower-priced substitutes and inconsistent product claims can further complicate purchasing decisions. Companies need robust pharmacovigilance, traceable sourcing, clear evidence and resilient manufacturing to maintain trust and protect market position during disruption.

Covid-19 Impact:

The COVID-19 pandemic disrupted veterinary appointments, specialist retail, travel and pet-care supply chains, while shifting more purchasing and advice-seeking online. Some owners postponed non-urgent services, but increased time at home and heightened attention to animal wellbeing supported demand for home-use products and digital support. Providers responded with e-commerce, teleconsultation and flexible scheduling. As restrictions eased, in-person services recovered, but demand for convenience and clear product information remained. The effect varied by market, depending on clinical need, discretionary spending and reliance on in-person experiences where available.

The Core Vaccines segment is expected to be the largest during the forecast period

The Core Vaccines segment is expected to account for a leading share of the pet vaccines market during the forecast period. Its position reflects the relevance of this group to the addressable companion-animal population and the breadth of use across the market's principal vaccine type applications. Established product availability, owner familiarity and professional recommendations support demand, while a wide range of care needs encourages repeat purchasing or service use. Market participants are expected to prioritize this segment through targeted product development, broader distribution and clearer use guidance.

The Other Companion Animals segment is expected to have the highest CAGR during the forecast period

The Other Companion Animals segment is expected to have the highest CAGR during the forecast period as providers expand targeted solutions and improve access through veterinary, specialist retail and digital channels. Demand is supported by growing awareness of the relevant need, improved product formulation or service delivery, and increased owner willingness to invest in tailored companion-animal care. As evidence, convenience and availability improve, this segment may attract new entrants and encourage established providers to broaden their portfolios.

Region with largest share:

North America is expected to account for a leading share of the pet vaccines market, supported by high companion-animal ownership, comparatively developed veterinary infrastructure, established pet specialty retail and relatively high per-pet expenditure. The United States represents a major demand center because owners have access to veterinary clinics, online pet-care platforms and a broad selection of specialized products and services. Canada contributes through a mature pet-care ecosystem and established companion-animal health providers. Market adoption is also supported by insurance availability, consumer awareness and product innovation, although adoption differs by income, geography and veterinary access.

Region with highest CAGR:

Asia Pacific is expected to exhibit strong growth in the pet vaccines market as pet ownership, urban household formation, veterinary service availability and organized pet retail expand across major markets. China, Japan, South Korea, India and Australia offer different adoption pathways, reflecting differences in purchasing power, veterinary infrastructure, product regulation and the role of digital commerce. Growing awareness of preventive care and rising demand for premium companion-animal products are likely to support market development. Expansion will depend on localized products, professional education and compliance with national animal-health and consumer-protection requirements.

Key players in the market

Some of the key players in the Global Pet Vaccines Market include Zoetis Inc., Merck Animal Health, Boehringer Ingelheim Animal Health, Elanco Animal Health, Ceva Sante Animale, Virbac, Vaxxinova, Bioveta, a.s., Indian Immunologicals Limited, Hester Biosciences Limited, Phibro Animal Health Corporation, Dechra Pharmaceuticals PLC, Vetoquinol, HIPRA, Bimeda, CZ Veterinaria S.A., Ourofino Saude Animal.

Key Developments:

In June 2026, Elanco Animal Health announced USDA approval of a low-volume combination vaccine designed to protect dogs against Lyme disease and leptospirosis in a single dose.

In March 2026, Merck Animal Health announced Canadian approval of its RNA-particle rabies vaccine for dogs and cats, adding a next-generation companion-animal immunization option.

In January 2026, Virbac announced the introduction of Canixin L, an L2 leptospirosis vaccine for dogs designed to reduce infection and associated clinical signs and shedding.

Vaccine Types Covered:

• Core Vaccines
• Non-Core Vaccines
• Combination Vaccines
• Emerging and Therapeutic Vaccines

Animal Types Covered:

• Dogs
• Cats
• Rabbits and Ferrets
• Other Companion Animals

Disease Indications Covered:

• Viral Diseases
• Bacterial Diseases
• Vector-Borne Diseases
• Fungal and Other Infections

Route of Administration Covered:

• Injectable
• Intranasal
• Oral
• Other Routes

Distribution Channels Covered:

• Veterinary Hospitals and Clinics
• Specialty Veterinary Distributors
• Government and Public Procurement
• Veterinary Pharmacies

Vaccine Valencies Covered:

• Monovalent Vaccines
• Bivalent Vaccines
• Multivalent Combination Vaccines

End Users Covered:

• General Veterinary Practices
• Specialty and Emergency Hospitals
• Shelters and Animal Welfare Organizations
• Government and Institutional Programs

Regions Covered:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • Netherlands
  • Belgium
  • Sweden
  • Switzerland
  • Poland
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Malaysia
  • Singapore
  • Vietnam
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Colombia
  • Chile
  • Peru
  • Rest of South America
• Rest of the World (RoW)
  • Middle East
    • Saudi Arabia
    • United Arab Emirates
    • Qatar
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • Egypt
    • Morocco
    • Rest of Africa

What our report offers:

• Market share assessments for regional and country-level segments
• Strategic recommendations for new entrants
• Covers market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032, and 2034
• Market trends, including drivers, constraints, opportunities, threats, challenges, investment opportunities, and recommendations
• Strategic recommendations for key business segments based on market estimations
• Competitive landscape mapping and assessment of key industry trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends and assessment of the latest technological advancements

Free Customization Offerings:

All customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, forecasts, and CAGR of any prominent country as per the client's interest (subject to feasibility assessment)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances